Ritalin Ireland (methylphenidate) indicates a central nervous system stimulant. In principle, it affects the chemicals in the brain and nerves, which contribute to both hyperactivity and impulse control. Ritalin Ireland is commonly used to treat attention deficit (ADD), narcolepsy and attention deficit hyperactivity disorder (ADHD).
Methylphenidate may form a habit. Therefore, do not share this medicine with others, especially anyone with a history of substance abuse and / or addiction. Improper use of Ritalin Ireland can lead to heart death and other serious side effects.
Methylphenidate treats attention deficit hyperactivity disorder (ADHD) by affecting the reuptake of the neurotransmitters noradrenaline and dopamine, while increasing the concentration in the nerve synapse (ie the space between the two nerves).
In principle, methylphenidate consists of two enantiomers (i.e. optical isomers): l-threo and d-threo. The D-threo enantiomer is more pharmacologically active than the 1-threo enantiomer (available under the tradename “dexmethylphenidate”). Methylphenidate belongs to a group of medicines called central nervous system stimulants.
Avoid using Ritalin if you have already used an MAOI in the last 14 days, as it may cause dangerous drug interactions. MAO inhibitors include linezolid, isocarboxazid, phenelzine, methylene blue injection, selegiline, tranylcypromine and rasagiline.
Use is contraindicated if you are allergic to Ritalin or if you have any of the following:
- family or personal history of ticks (eg muscle spasms) and / or Tourette’s syndrome;
Severe tension, anxiety or agitation (these medicines may make these symptoms worse).
Certain stimulants have historically caused sudden death in many people. So, tell your doctor if you have any of the following:
- High blood pressure;
- congenital heart failure and / or heart problems;
To make sure that Ritalin is completely safe for you, tell your doctor if you or any of your family members have ever had:
- movement cramps (muscle cramps) or Tourette’s syndrome;
- depression, bipolar disorder, mental illness, suicidal ideation and / or behavior, psychosis;
- circulatory problems in the hands or feet;
- epilepsy or seizures;
- problems with the stomach, esophagus or intestines;
- abnormal electroencephalography (EEG);
History of alcohol or drug addiction.
Methylphenidate can impair patient judgment and / or responsiveness and make the handling and operation of machinery very difficult and dangerous. Therefore, do not operate or operate machinery if methylphenidate affects you in this way.
In the event of an overdose, seek medical advice immediately or call 1-800-222-1222 for poison assistance. Methylphenidate overdose can be fatal.
Methylphenidate (the active substance in Ritalin Island) can cause unwanted side effects that need immediate treatment.
The main side effects of Ritalin Ireland are:
- chest pain;
- skin rash or hives;
- joint pain.
- tarry and black stools;
- blood in the stool or urine;
- blurred vision and / or other noticeable changes in vision;
- dry skin, scabs or peeling;
- Noticeable red spots on the skin;
- uncontrolled sounds and / or ticks (i.e., repetitive, uncontrolled body movements);
- severe redness, flaking, swelling or soreness of the skin;
- Abnormal bruising or bleeding.
Typical doses for attention deficit disorder in adults include: immediate release tablets (including chewable tablets), i.e., Ritalin, methylphenidate, methylline.
The initial dose of 10 mg should be taken orally 2-3 times a day, preferably 30-45 minutes before breakfast and lunch, and the third dose should be taken 14-16 minutes if needed. Patients who have trouble sleeping at night during treatment with methylphenidate should take their last medicine before 18:00.
Maintenance dose: The maximum daily dose is 60 mg, which can be increased in increments of 5-10 mg per week. For some patients, 10 to 15 mg per day may be sufficient. In patients who have problems sleeping at night during treatment with methylphenidate, the last dose should be taken before 18.00.
Impact and response time
The time required to release the product immediately after reaching the highest methylphenidate concentration is approximately 1.9 hours.
Sustained-release capsules or tablets have a two-stage release system. The initial peak concentration is reached within the first hour after administration and the next peak is reached within about 3 hours.